YolTech Therapeutics Achieves Major Funding Milestone
YolTech Therapeutics, a pioneering force in in vivo genome editing therapies, has announced a successful Series B financing round, raising approximately $45 million. This funding was prominently led by the AstraZeneca-CICC healthcare investment fund, marking a significant milestone in the company’s journey.
Advancing Innovative Therapeutic Solutions
Dr. Yuxuan Wu, the Founder and CEO of YolTech, expressed enthusiasm, stating that this financing is a pivotal moment as the company progresses with its clinical pipeline. The funds will be utilized to push forward their cutting-edge gene-editing programs. YolTech is committed to transforming the latest advances in gene editing into real-world therapies that can provide meaningful benefits to patients globally.
About YolTech Therapeutics
Founded in 2021, YolTech Therapeutics specializes in developing next-generation in vivo gene-editing therapies intended for one-time administration. The company has established a robust platform that includes proprietary CRISPR nucleases known as YolCas, innovative base editors named YolBE, and an advanced lipid nanoparticle delivery system referred to as Yol-LNPs. This unique combination allows for accurate, efficient, and tissue-specific gene editing across a wide variety of therapeutic areas.
Significant Milestones in Clinical Research
In a remarkable achievement, YolTech's lead program YOLT-201, a CRISPR-based therapy addressing transthyretin amyloidosis (ATTR), became the first in vivo gene-editing therapy in the region to begin Phase I/IIa clinical trials. Since this initial clinical trial, the company has further advanced four additional clinical-stage programs targeting conditions such as ATTR, familial hypercholesterolemia (HeFH), primary hyperoxaluria type 1 (PH1), and ?-thalassemia/sickle cell disease (TDT/SCD).
Ensuring Quality Manufacturing
YolTech proudly operates a cGMP-compliant manufacturing facility that supports clinical supply through to Phase III and early commercial scaling. This commitment to quality guarantees manufacturing consistency and scalability, which are critical elements in the company’s ongoing programs.
Leadership in the Gene-Editing Field
With one of the most comprehensive in vivo gene-editing clinical pipelines on a global scale, YolTech is consistently at the forefront of innovation in the field. The company’s base-editing therapy YOLT-101, designed for familial hypercholesterolemia (HeFH), notably became the first in vivo base-editing program to secure IND clearance in both China and the United States.
Frequently Asked Questions
What is the purpose of YolTech Therapeutics?
YolTech Therapeutics focuses on developing innovative in vivo gene-editing therapies to create effective, one-time treatments for various genetic diseases.
How much funding did YolTech recently secure?
YolTech Therapeutics successfully raised approximately $45 million in its Series B financing round.
Who led the recent funding for YolTech?
The funding round was led by the AstraZeneca-CICC healthcare investment fund.
What are the key therapies being developed by YolTech?
YolTech is working on therapies targeting transthyretin amyloidosis (ATTR), familial hypercholesterolemia (HeFH), primary hyperoxaluria type 1 (PH1), and ?-thalassemia/sickle cell disease (TDT/SCD).
When was YolTech founded?
YolTech Therapeutics was founded in 2021, positioning itself as a leader in the gene-editing space.
